Patent · US Active

Extended release venlafaxine tablet formulation

US8105627B2 · kind B2 · utility

0Cited by
11References
27Claims
0Family size

Assignee

Inventors

Key dates

Filing dateDec 11, 2003
Grant dateJan 31, 2012
Priority date
Expiry dateApr 2, 2027

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K9/2054
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

An extended release formulation for administration of venlafaxine in an oral tablet dosage form. The formulation preferably features a core, over which an outer coating is layered. The core preferably contains venlafaxine, a filler, and a water soluble cellulosic polymer, optionally and more preferably with a water insoluble cellulosic polymer. The core is preferably coated with a coating material. The coating preferably contains a mixture of water soluble cellulosic polymer and a water insoluble cellulosic polymer. According to a first embodiment of the present invention, the filler is preferably present in an amount of at least about 40% weight per weight of the total formulation. More preferably, the filler comprises microcrystalline cellulose. Most preferably, the filler solely comprises microcrystalline cellulose. Also most preferably, microcrystalline cellulose is present in the core in a range of from about 45% to about 65% weight per weight of the total formulation.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.